Aptevo Therapeutics (APVO) Net Cash Flow (2016 - 2023)
Historic Net Cash Flow for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to -$1.9 million.
- Aptevo Therapeutics' Net Cash Flow rose 7437.84% to -$1.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$3.5 million, marking a year-over-year increase of 8873.76%. This contributed to the annual value of -$5.7 million for FY2023, which is 7578.06% up from last year.
- Aptevo Therapeutics' Net Cash Flow amounted to -$1.9 million in Q3 2023, which was up 7437.84% from -$4.3 million recorded in Q2 2023.
- In the past 5 years, Aptevo Therapeutics' Net Cash Flow registered a high of $17.3 million during Q3 2020, and its lowest value of -$16.0 million during Q2 2019.
- Its 5-year average for Net Cash Flow is -$997210.5, with a median of -$4.3 million in 2023.
- As far as peak fluctuations go, Aptevo Therapeutics' Net Cash Flow crashed by 72031.01% in 2019, and later skyrocketed by 62971.9% in 2020.
- Aptevo Therapeutics' Net Cash Flow (Quarter) stood at -$5.2 million in 2019, then surged by 387.24% to $15.0 million in 2020, then crashed by 147.04% to -$7.1 million in 2021, then soared by 100.83% to $59000.0 in 2022, then crashed by 3313.56% to -$1.9 million in 2023.
- Its Net Cash Flow was -$1.9 million in Q3 2023, compared to -$4.3 million in Q2 2023 and $2.7 million in Q1 2023.